Abstract
Imiquimod (IMQ) is often used as a topical challenge agent to provoke local skin inflammation. The objective of this study was to develop and refine a rapid, temporary, and reversible human skin inflammation model with IMQ for application in clinical drug development. A randomized, vehicle-controlled, open-label, dose-ranging study was conducted in 16 healthy male subjects. IMQ (5 mg) was applied once daily for 72 hours under occlusion to intact skin (n = 8) or tape stripped (TS) skin (n = 8). Although IMQ alone induced limited effects, TS+IMQ treatment showed larger responses in several domains, including erythema and perfusion (P < 0.0001), mRNA expression of inflammatory markers (P < 0.01), and inflammatory cell influx compared with vehicle. In conclusion, a rapid, human IMQ skin inflammation challenge model was successfully developed with a clear benefit of TS prior to IMQ application. Future interaction studies will enable proof-of-pharmacology of novel compounds targeting the innate immune system.
References
Nov 1, 1996·British Journal of Pharmacology·A Burke-Gaffney, P G Hellewell
Mar 5, 1998·Journal of the American Academy of Dermatology·K R BeutnerJ M Douglas
Feb 14, 2004·The Australasian Journal of Dermatology·Jason K WuGeoff Strutton
Feb 24, 2004·The Journal of Immunology : Official Journal of the American Association of Immunologists·Javier Mestas, Christopher C W Hughes
Jul 7, 2005·The Journal of Experimental Medicine·Frank O NestleMichel Gilliet
Nov 29, 2005·Clinical and Experimental Dermatology·N Rajan, J A A Langtry
Dec 3, 2005·European Journal of Immunology·Chiara OttavianiAndrea Cavani
Dec 23, 2006·International Journal of Dermatology·P A FantiC Varotti
Dec 11, 2007·The British Journal of Dermatology·M P Schön, M Schön
Apr 4, 2008·The New England Journal of Medicine·Manon van SetersTheo J M Helmerhorst
Apr 4, 2008·The New England Journal of Medicine·Thomas Bieber
Apr 22, 2009·The Journal of Immunology : Official Journal of the American Association of Immunologists·Leslie van der FitsErik Lubberts
Jul 31, 2009·The New England Journal of Medicine·Frank O NestleJonathan Barker
Dec 17, 2009·Expert Reviews in Molecular Medicine·Emoke Rácz, Errol P Prens
Nov 11, 2010·The British Journal of Dermatology·U PatelV J Levine
Dec 1, 2010·The Journal of Experimental Medicine·Josh GregorioMichel Gilliet
May 23, 2012·Pediatric Dermatology·Wallace A SmithKristen E Holland
Nov 21, 2013·European Journal of Immunology·Barry Flutter, Frank O Nestle
Jan 7, 2014·The Journal of Dermatology·Azumi UeyamaKiyoshi Yasui
Apr 12, 2014·Nature Reviews. Immunology·Manolis PasparakisFrank O Nestle
Jul 2, 2014·The British Journal of Dermatology·H VinterC Johansen
Jan 19, 2015·Inflammation Research : Official Journal of the European Histamine Research Society ... [et Al.]·Marion C DicksonMichael H Binks
May 31, 2015·Lancet·Wolf-Henning Boehncke, Michael P Schön
Dec 14, 2016·The Journal of Investigative Dermatology·Jason E HawkesNicole L Ward
Citations
Feb 12, 2020·Clinical and Translational Science·Tessa Niemeyer-van der KolkMatthijs Moerland
Apr 8, 2020·British Journal of Clinical Pharmacology·Robert RissmannMartijn B A van Doorn
Apr 22, 2020·Clinical and Translational Science·Tessa Niemeyer-van der KolkMartijn B A van Doorn
Jul 23, 2021·British Journal of Clinical Pharmacology·Thomas P ButersMatthijs Moerland